Here, in this study, we successfully produced RTX-containing NPs loaded with CP and anti-Nrf2 siRNA (NP-Nrf2_siRNA-CP) and targeted CLL cells with them for the first time. This evidence concerns the gene CP and B-cell chronic lymphocytic leukemia.